Objectives: Hacer un abordaje sencillo y claro de las lesiones cutáneas en pacientes con neoplasias de base, pasando por sus simuladores y evaluando la epidemiología asociada a este tipo de hallazgos en piel.
Introduction: 66-year-old female patient, with history of diffuse large cell non-Hodgkin lymphoma, in treatment with R-CHOP therapy with an inadequate response. During her hospital stay, the patient was referred to dermatology consult due to a 3-day history of lesions in the anterior thorax associated with burning pain and pruritus. Upon physical exam, she presented with multiple erythematous and edematous plaques with irregular, well-defined edges who merged in the left parasternal region.
Materials / method: Herpes zoster was initially suspected, leading to IV acyclovir treatment due to her immunocompromised status. Because there was no satisfactory response, a skin biopsy was performed.
Pathology report showed the presence of an infiltrate with a neoplastic appearance that extended to the reticular dermis, lymphocytes with prominent nucleus, and a high mitotic rate. Immunohistochemistry with revealed a population of neoplastic cells which marked positive for common leukocyte antigen, CD20, BCL2, FOXP1 and MMU1 with Ki67 a 90% positivity.
Results: Diffuse large B-cell lymphoma (CBCL) is the most common type of B cell lymphoma, accounting for 30 to 50% of all non-Hodgkin lymphoma cases. However, its clinical manifestations on the skin are atypical and infrequent. Its presentation is aggressive and can be expressed in different clinical forms . It is more common in individuals older than 60 years as a novelty presentation or due to the transformation of small cell non-Hodgkin lymphoma . Its symptoms will depend on tumor location and up to 30% of cases can be associated with constitutional symptoms.
Conclusion: B-cell lymphoma is a frequently reported pathology, however; skin involvement is an infrequent manifestation and can easily be confused with other diseases. Its course is generally aggressive with a high burden of morbidity and mortality despite targeted and timely treatment.
Disclosures
Did you receive any funding to support your research for this TOPIC?
No
Were you provided with any honoraria, payment or other compensation for your work on this study?
No
Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No
Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No
This work was not supported by any direct or non direct funding. It is under the author's own responsability